Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.5BCash, Pro Forma
61.1mo Cash Runway
Follow SYRE by emailGet an email when SYRE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SYRE, unsubscribe in one click. Privacy
📣 What SYRE Says Is Next
in 2027 · “The Company is currently enrolling its SPY120, SPY130, and SPY230 combinations in Part B of the SKYLINE trial, with an expected induction read-out in 2027.”
Company press release, Nov 3, 2026 · SEC filing
third quarter of 2027 · SPY001: “Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept, and contribution of components for combinations, with induction data expected in the third quarter of 2027.”
Company press release, Nov 3, 2026 · SEC filing
in 2027 · “Additionally, the Company plans to advance a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027.”
Company press release, Nov 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 3, 2026 ·
Earnings Reported Q3 2026 results with $1.5 billion in pro forma cash, equivalents and marketable securities as of Sept 30, 2026, runway into 2H 2029, after an October offering raising over $400 million. SPY072 failed to advance in rheumatic diseases. Form 8-K · SEC filing · Press release
Oct 7, 2026 ·
Financing Spyre agreed to sell 4,117,648 common shares at $85.00 per share in an underwritten offering, with a 30-day option for 617,647 more. Gross proceeds are expected to be about $350.0 million, closing on or about October 7, 2026. Form 8-K · SEC filing
Oct 6, 2026 ·
Financing Spyre Therapeutics is offering 4,117,648 shares of common stock at $85.00 per share, for gross proceeds of $350,000,080, with underwriters holding an option to buy up to 617,647 more shares. Expected delivery is on or about October 7, 2026. Form 424B5 · SEC filing
Oct 5, 2026 ·
Financing Spyre Therapeutics proposed a public offering of its common stock, with the number of shares and price left blank in this preliminary prospectus. The stock closed at $93.19 on October 2, 2026, and underwriters have a 30-day option for additional shares. Form 424B5 · SEC filing
Sep 8, 2026 ·
Clinical trial Spyre reported positive 12-week Part A induction results for SPY003 (anti-IL-23) in the Phase 2 SKYLINE trial in ulcerative colitis. The primary endpoint was met with a 10.0-point RHI reduction (p<0.0001), clinical remission was 20%, and endoscopic improvement was 30%. Safety was consistent with the IL-23 class. Form 8-K · SEC filing · Press release
Aug 25, 2026 ·
Clinical trial Reported topline RA sub-study results for SPY072: low dose met the primary DAS28-CRP endpoint vs placebo (-1.9 vs -1.3, p<0.05), with nominal ACR20 gains at high dose (63% vs 43%). Safety was comparable to placebo. Results did not meet the bar to prioritize RA monotherapy. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 1 · Active Trial · A Study of SPY003-207 in Healthy Volunteers Registry primary completion date, not a results date
Jun 2027 · Phase 2 · Recruiting · A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Registry primary completion date, not a results date
Oct 2027 · Phase 2 · Recruiting · A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) Registry primary completion date, not a results date
Mar 2029 · Phase 2 · Enrolling · Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD Registry primary completion date, not a results date
Oct 2026 · Phase 2 · Active Trial · A Study of SPY072 in Rheumatic Disease Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not SYRE's own candidates): Bimekizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SYRE had $1.1B in cash and short-term investments on its Sep 30, 2026 balance sheet.
Including the cash events since then, it holds about $1.5B pro forma, before operating spending after that date:
Company-stated pro forma cash at Sep 30, 2026 (release of Nov 3, 2026): $1.5B in total · 8-K
It burns about $73.7M/quarter from operations, an estimated runway of 61.1 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:17 · Low
Cash runway 61 months (pro forma for cash events since the balance sheet)
ATM program on file since Jun 2026 +15
Shelf registration (S-3ASR, Jun 2026) +10
Company says cash lasts into the second half of 2029 -15We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2026, together with the net proceeds from the October 2026 Offering and sales under the 2026 Sales Agreement subsequent to September 30, 2026, will be sufficient to fund our planned operating expenses and capital…10-Q, Nov 2026
Share count +22% in a year +7
Recent financing filings on SEC EDGAR:
Oct 6, 2026 · Underwritten offering, $350M · 424B5
Share count 94,969,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SYRE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SYRE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.